Fmr LLC Boosts Holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Fmr LLC increased its holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 0.2% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,570,078 shares of the company’s stock after purchasing an additional 26,431 shares during the period. Fmr LLC owned approximately 14.95% of Poseida Therapeutics worth $41,670,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in PSTX. Vanguard Group Inc. boosted its position in Poseida Therapeutics by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after buying an additional 473,746 shares during the period. Renaissance Technologies LLC boosted its holdings in Poseida Therapeutics by 53.4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock valued at $2,496,000 after acquiring an additional 297,500 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Poseida Therapeutics by 62.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock valued at $1,027,000 after acquiring an additional 138,510 shares during the period. Blair William & Co. IL increased its stake in Poseida Therapeutics by 14.1% in the 2nd quarter. Blair William & Co. IL now owns 1,101,325 shares of the company’s stock worth $3,216,000 after purchasing an additional 136,273 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in Poseida Therapeutics in the 2nd quarter worth approximately $241,000. Institutional investors own 46.87% of the company’s stock.

Insiders Place Their Bets

In related news, Chairman Mark J. Gergen sold 30,000 shares of Poseida Therapeutics stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total transaction of $278,100.00. Following the sale, the chairman now directly owns 651,291 shares in the company, valued at $6,037,467.57. The trade was a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on PSTX. BTIG Research restated a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Cantor Fitzgerald cut shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 26th. William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. HC Wainwright restated a “neutral” rating and set a $9.00 price target (down previously from $20.00) on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Finally, Piper Sandler cut Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price objective for the company. in a report on Monday, December 2nd. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $9.50.

Poseida Therapeutics Trading Up 0.3 %

NASDAQ:PSTX opened at $9.36 on Friday. The company has a 50-day moving average price of $3.89 and a 200-day moving average price of $3.31. The stock has a market cap of $912.23 million, a price-to-earnings ratio of -14.86 and a beta of 1.64. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. Poseida Therapeutics, Inc. has a 12 month low of $1.87 and a 12 month high of $9.44.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.